CTAD 2023: Roche’s Trontinemab Shows Rapid, Deep Amyloid Clearance Lacking From Gantenerumab
Ongoing Study Will Expand Before Next Trial Begins
The first clinical trial results for Roche’s brain shuttle technology in Alzheimer’s patients showed that trontinemab cleared more amyloid and at a faster pace than its failed predecessor gantenerumab.
You may also be interested in...
Scrip spoke with Roche Pharmaceuticals CEO Teresa Graham about efforts to boost product sales, build out the drug development portfolio and return the company to revenue growth.
In this week's podcast edition of Five Must-Know Things: CEOs on global tensions; Roche’s new Alzheimer's contender; Sanofi eyes external deals; investors’ reactions to clinical data; and Korean licensing pitfalls
Neuroscience is increasingly a focus for the Swiss pharma giant, and it believes it can stay ahead in multiple sclerosis with fenebrutinib, while making up lost ground in with two key candidates in Alzheimer’s disease.